In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target
2017 · Nature · 1,101 citations
https://doi.org/10.1038/nature23270
K
Kevin Bi
Broad Institute(US)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
74
Papers
7.3K
Citations
20
h-index
22
i10-index
Kevin Bi is an academic researcher from Broad Institute. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Cancer Genomics and Diagnostics & Immunotherapy and Immune Responses. The author has an h-index of 20, co-authored 63 publications.
ORCID: 0000-0002-6794-1804Papers by this author
worksTumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma
2021 · Cancer Cell · 583 citations
https://doi.org/10.1016/j.ccell.2021.02.015
MultispeQ Beta: a tool for large-scale plant phenotyping connected to the open PhotosynQ network
2016 · Royal Society Open Science · 410 citations
https://doi.org/10.1098/rsos.160592
Transcriptional mediators of treatment resistance in lethal prostate cancer
2021 · Nature Medicine · 188 citations
https://doi.org/10.1038/s41591-021-01244-6
Cell states and neighborhoods in distinct clinical stages of primary and metastatic esophageal adenocarcinoma
2025 · Cell Reports Medicine · 4 citations
https://doi.org/10.1016/j.xcrm.2025.102188
Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma
2025 · Cancer Cell · 3 citations
https://doi.org/10.1016/j.ccell.2025.05.009
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat